Xeris Biopharma Holdings, Inc. Share Price
XERSXeris Biopharma Holdings, Inc. Stock Performance
Open $5.55 | Prev. Close $5.45 | Circuit Range N/A |
Day Range $5.41 - $5.61 | Year Range $3.81 - $10.07 | Volume 43,269 |
Average Traded $5.48 |
Xeris Biopharma Holdings, Inc. Share Price Chart
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
13-Mar-26 | $5.53 | $5.46 | -0.55% |
12-Mar-26 | $5.60 | $5.49 | -4.52% |
11-Mar-26 | $5.74 | $5.75 | -1.12% |
10-Mar-26 | $5.59 | $5.82 | +3.84% |
09-Mar-26 | $5.78 | $5.60 | -3.61% |
06-Mar-26 | $5.90 | $5.81 | -3.89% |
05-Mar-26 | $6.08 | $6.04 | -0.33% |